
In re Application of:

Marc R. Montminy

Application No.: Unassigned Filed: February 29, 2000

Page 2



IN THE CLAIMS

Please amend claims 12 and 17 as noted below. For the Examiner's convenience, all pending claims are presented, with those not being amended at this time marked "reiterated."


- 1. (Reiterated) A method for treating diabetes mellitus, said method comprising contacting a biological system with an effective amount of a compound which inhibits binding of CREB to CBP.
- 2. (Reiterated) A method according to claim 1 wherein said treatment of diabetes mellitus ameliorates hyperglycemia.
 - 3. (Reiterated) A method according to claim 2 wherein gluconeogenesis is modulated.
- 4. (Reiterated) A method according to claim 3 wherein transcription of PEPCK is inhibited.
- 5. (Reiterated) A method according to claim 2 wherein transcription of glucogon gene is inhibited.
- 6. (Reiterated) A method according to claim 1 wherein said biological system is an infact organism.
- 7. (Reiterated) A method according to claim 1 wherein said contacting is carried out by oral, intravenous, subcutaneous, intramuscular or intracutaneous mode of administration.

In re Application of:

Marc R. Montminy

Application No.: Unassigned Filed: February 29, 2000

Page 3



12. (Amended) A method for treating diabetes mellitus, comprising contacting a biological system with an effective amount of a compound [identified by the method of claim 8] which disrupts complex comprising cyclic AMP response element binding protein (CREB) and CREB binding protein (CBP), said compound identified by a method comprising:

(a) contacting a modified host cell with a test compound, wherein said modified host cell comprises:

a first fusion protein comprising a GAL4 DNA binding domain, operatively associated with the kinase-inducible domain (KID) of CREB,

a second fusion protein comprising an activation domain, operatively associated with the CREB binding domain (KIX) of CBP, and

a reporter construct comprising a GAL4 response element operatively linked to a reporter gene; and

- (b) selecting those test compounds which cause reduced expression of the reporter gene product, wherein said compounds are identified as disrupting complex comprising CREB and CBP.
- 17. (Amended) A method for treating diabetes mellitus, comprising contacting a biological system with an effective amount of a compound [identified by the method of claim 13] which disrupts complex comprising cyclic AMP response element binding protein (CREB) and CREB binding protein (CBP), said compound identified by a method comprising:
 - (a) contacting a modified host cell with a test compound, wherein said modified host cell comprises:

a first fusion protein comprising an activation domain, operatively associated with the kinase-inducible domain (KID) of CREB,

a second fusion protein comprising a GAL4 DNA binding domain, operatively associated with the CREB binding domain (KIX) of CBP, and